These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10400646)

  • 1. Protein adducts of iso[4]levuglandin E2, a product of the isoprostane pathway, in oxidized low density lipoprotein.
    Salomon RG; Sha W; Brame C; Kaur K; Subbanagounder G; O'Neil J; Hoff HF; Roberts LJ
    J Biol Chem; 1999 Jul; 274(29):20271-80. PubMed ID: 10400646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidation of low-density lipoproteins produces levuglandin-protein adducts.
    Salomon RG; Subbanagounder G; Singh U; O'Neil J; Hoff HF
    Chem Res Toxicol; 1997 Jul; 10(7):750-9. PubMed ID: 9250408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in the isoprostane pathway: identification of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and characterization of their protein adducts.
    Roberts LJ; Salomon RG; Morrow JD; Brame CJ
    FASEB J; 1999 Jul; 13(10):1157-68. PubMed ID: 10385607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage recognition of LDL modified by levuglandin E2, an oxidation product of arachidonic acid.
    Hoppe G; Subbanagounder G; O'Neil J; Salomon RG; Hoff HF
    Biochim Biophys Acta; 1997 Jan; 1344(1):1-5. PubMed ID: 9022751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iso[7]LGD2-protein adducts are abundant in vivo and free radical-induced oxidation of an arachidonyl phospholipid generates this D series isolevuglandin in vitro.
    Poliakov E; Meer SG; Roy SC; Mesaros C; Salomon RG
    Chem Res Toxicol; 2004 May; 17(5):613-22. PubMed ID: 15144218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing levuglandins produced through the cyclooxygenase and isoprostane pathways.
    Salomon RG
    Chem Phys Lipids; 2005 Mar; 134(1):1-20. PubMed ID: 15752459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levuglandin E2-protein adducts in human plasma and vasculature.
    Salomon RG; Subbanagounder G; O'Neil J; Kaur K; Smith MA; Hoff HF; Perry G; Monnier VM
    Chem Res Toxicol; 1997 May; 10(5):536-45. PubMed ID: 9168251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation and stability of pyrrole adducts in the reaction of levuglandin E2 with proteins.
    DiFranco E; Subbanagounder G; Kim S; Murthi K; Taneda S; Monnier VM; Salomon RG
    Chem Res Toxicol; 1995; 8(1):61-7. PubMed ID: 7703368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo.
    Poliakov E; Brennan ML; Macpherson J; Zhang R; Sha W; Narine L; Salomon RG; Hazen SL
    FASEB J; 2003 Dec; 17(15):2209-20. PubMed ID: 14656983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway.
    Salomon RG; Batyreva E; Kaur K; Sprecher DL; Schreiber MJ; Crabb JW; Penn MS; DiCorletoe AM; Hazen SL; Podrez EA
    Biochim Biophys Acta; 2000 May; 1485(2-3):225-35. PubMed ID: 10832102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levuglandins and isolevuglandins: stealthy toxins of oxidative injury.
    Salomon RG
    Antioxid Redox Signal; 2005; 7(1-2):185-201. PubMed ID: 15650407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts.
    Brame CJ; Salomon RG; Morrow JD; Roberts LJ
    J Biol Chem; 1999 May; 274(19):13139-46. PubMed ID: 10224068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the lysyl adducts of prostaglandin H-synthases that are derived from oxygenation of arachidonic acid.
    Boutaud O; Brame CJ; Chaurand P; Li J; Rowlinson SW; Crews BC; Ji C; Marnett LJ; Caprioli RM; Roberts LJ; Oates JA
    Biochemistry; 2001 Jun; 40(23):6948-55. PubMed ID: 11389610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total Synthesis Confirms the Molecular Structure Proposed for Oxidized Levuglandin D
    Cheng YS; Yu W; Xu Y; Salomon RG
    J Nat Prod; 2017 Feb; 80(2):488-498. PubMed ID: 28195470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Carboxyalkyl)pyrroles in human plasma and oxidized low-density lipoproteins.
    Kaur K; Salomon RG; O'Neil J; Hoff HF
    Chem Res Toxicol; 1997 Dec; 10(12):1387-96. PubMed ID: 9437530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase.
    Gao L; Zackert WE; Hasford JJ; Danekis ME; Milne GL; Remmert C; Reese J; Yin H; Tai HH; Dey SK; Porter NA; Morrow JD
    J Biol Chem; 2003 Aug; 278(31):28479-89. PubMed ID: 12746435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin endoperoxides 21. Covalent binding of levuglandin E2 with proteins.
    Salomon RG; Jirousek MR; Ghosh S; Sharma RB
    Prostaglandins; 1987 Nov; 34(5):643-56. PubMed ID: 3481092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of oxidation in plasma Lp(a) in CAPD patients using a novel ELISA.
    Podrez EA; O'Neil J; Salomon RG; Schreiber MJ; Hoff HF
    Kidney Int; 1998 Aug; 54(2):637-45. PubMed ID: 9690232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolevuglandin adducts in disease.
    Salomon RG; Bi W
    Antioxid Redox Signal; 2015 Jun; 22(18):1703-18. PubMed ID: 25557218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levuglandin E2 crosslinks proteins.
    Iyer RS; Ghosh S; Salomon RG
    Prostaglandins; 1989 Apr; 37(4):471-80. PubMed ID: 2762557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.